LIPT2: A Key Enzyme in Fatty Acid Production and Cellular Processes
LIPT2: A Key Enzyme in Fatty Acid Production and Cellular Processes
LIPT2 (Lipoyl (octanoyl)-[acyl-carrier-protein]-protein N-lipoyltransferase) is a protein that is expressed in various tissues of the body, including muscle, heart, brain, and kidney. It is a key enzyme in the transfer of N-lipoyl (NL) to target proteins, which is a crucial step in the production of fatty acids, such as leucine, from tryptophan, the amino acid that makes up protein.
The function of LIPT2 is to transfer N-lipoyl to the target protein via a protein-protein interaction. This interaction involves the formation of a N-lipoyl carrier protein (NLCP) and the transfer of the N-lipoyl to the target protein via a nucleotide-binding oligomerization (NBO) domain. The NLCP is a protein that contains a nucleotide-binding oligomerization domain and is responsible for carrying the N-lipoyl to the target protein.
LIPT2 is a member of the superfamily of N-acyl transferases (NATs), which are a group of enzymes that transfer a negatively charged fatty acid, such as acyl-CoA, to a target protein via a protein-protein interaction. NATs are involved in a wide range of cellular processes, including metabolism, signal transduction, and cellular signaling.
LIPT2 is also involved in the production of fatty acids from tryptophan, which is a critical amino acid for the synthesis of proteins and other molecules. In addition, LIPT2 is involved in the regulation of cellular processes such as cell growth, apoptosis, and inflammation.
Due to its involvement in the production of fatty acids and its role in various cellular processes, LIPT2 has been identified as a potential drug target or biomarker. Several studies have suggested that LIPT2 may be a promising target for drugs that are designed to regulate the production of fatty acids or to promote cellular processes, such as cell growth and apoptosis.
One of the potential benefits of targeting LIPT2 is that it may be able to treat a wide range of diseases and disorders that are caused by the production of abnormal levels of fatty acids or the regulation of cellular processes. For example, LIPT2 has been suggested as a potential target for the treatment of various metabolic disorders, such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD).
In addition, LIPT2 has also been suggested as a potential target for the treatment of various neurological and psychiatric disorders, such as Alzheimer's disease, Parkinson's disease, and depression. These disorders are often characterized by the production of abnormal levels of certain fatty acids, such as omega-3 fatty acids, or by the regulation of cellular processes that are involved in neurotransmission.
Another potential benefit of targeting LIPT2 is that it may be able to improve the effectiveness of certain therapies. For example, LIPT2 has been suggested as a potential target for the treatment of cancer, as the production of fatty acids from tryptophan may be a critical step in the development and progression of many types of cancer. In addition, LIPT2 has also been suggested as a potential target for the treatment of certain infections, such as bacterial and fungal infections.
In conclusion, LIPT2 is a protein that is involved in the production of fatty acids and the regulation of cellular processes. It has been identified as a potential drug target or biomarker due to its involvement in the production of fatty acids and its role in various cellular processes. Further research is needed to fully understand the function and potential applications of LIPT2, and to develop effective therapies that can target this protein.
Protein Name: Lipoyl(octanoyl) Transferase 2
Functions: Catalyzes the transfer of endogenously produced octanoic acid from octanoyl-acyl-carrier-protein onto the lipoyl domains of lipoate-dependent enzymes, which catalyze essential redox reactions (PubMed:28757203). Lipoyl-ACP can also act as a substrate although octanoyl-ACP is likely to be the physiological substrate (By similarity)
The "LIPT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LIPT2 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LIPT2-AS1 | LITAF | Liver Bile Transporters (LBAT) | LIX1 | LIX1-AS1 | LIX1L | LKAAEAR1 | LKB1-LIP1-SMAD4 complex | LL22NC03-63E9.3 | LLCFC1 | LLGL1 | LLGL2 | LLPH | LMAN1 | LMAN1L | LMAN2 | LMAN2L | LMBR1 | LMBR1L | LMBRD1 | LMBRD2 | LMCD1 | LMCD1-AS1 | LMF1 | LMF2 | LMLN | LMNA | LMNB1 | LMNB2 | LMNTD1 | LMNTD2 | LMNTD2-AS1 | LMO1 | LMO2 | LMO3 | LMO4 | LMO7 | LMO7-AS1 | LMO7DN | LMOD1 | LMOD2 | LMOD3 | LMTK2 | LMTK3 | LMX1A | LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285
